Physician profile
Thomas L Oconnor
NPI 1760470033
$10,971.85
in general payments reported to CMS, 2019-2025
40 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $405 · 2021: $1,323 · 2022: $1,492 · 2023: $2,081 · 2024: $2,330 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,498 · Education: $39.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,497.71 |
| Education | $39.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,151.71 | 2019-2025 | |
| Janssen Biotech, INC. | $1,671.21 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,041.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $651.16 | 2020-2023 | |
| Genzyme Corporation | $616.17 | 2023-2025 | |
| Pfizer INC. | $548.99 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $543.73 | 2024-2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.24 | 2019-2023 | Xifaxan |
| Celgene Corporation | $421.07 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $203.77 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $198.15 | 2019-2025 | |
| Qol Medical, LLC | $147.34 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $133.01 | 2019-2023 | Dificid |
| Lilly USA, LLC | $132.42 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $88.41 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.